US 12,138,313 B2
Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
Hong Ren, Brighton, MA (US); Scott Michael Lonning, Westford, MA (US); Nels Eric Pederson, Mansfield, MA (US); Klarisa Rikova, Reading, MA (US); Aleksandr Tkachev, Cambridge, MA (US); and Tinglei Gu, Andover, MA (US)
Assigned to Bluefin Biomedicine, Inc., Beverly, MA (US)
Filed by Bluefin BioMedicine, Inc., Beverly, MA (US)
Filed on Mar. 21, 2024, as Appl. No. 18/612,088.
Application 18/320,885 is a division of application No. 16/469,197, granted, now 11,702,481, issued on Jul. 18, 2023, previously published as PCT/US2017/066661, filed on Dec. 15, 2017.
Application 18/612,088 is a continuation of application No. 18/320,885, filed on May 19, 2023.
Claims priority of provisional application 62/588,516, filed on Nov. 20, 2017.
Claims priority of provisional application 62/488,445, filed on Apr. 21, 2017.
Claims priority of provisional application 62/435,509, filed on Dec. 16, 2016.
Prior Publication US 2024/0287203 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01)
CPC A61K 47/68031 (2023.08) [A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/68035 (2023.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01)] 8 Claims
OG exemplary drawing
 
1. An antibody drug conjugate (ADC) that binds to CUB domain-containing protein 1 (CDCP1) comprising:
an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) comprising SEQ ID NO: 155 (HCDR1), SEQ ID NO: 156 (HCDR2), and SEQ ID NO: 157 (HCDR3), and a light chain variable region (VL) comprising SEQ ID NO: 158 (LCDR1), SEQ ID NO: 159 (LCDR2), and SEQ ID NO: 160 (LCDR3), and
monomethyl auristatin E (MMAE).